Yuanhua Zhiyi, Medvisis Partner on AI Drug Development

Yuanhua Zhiyi and Swiss company Medvisis are joining forces on artificial-intelligence-driven drug discovery and drug repurposing, combining Yuanhua Zhiyi’s Smart Orchestration Platform with multimodal AI technology. The collaboration matters because computational screening and integrated data analysis can help identify promising compounds and new uses for existing medicines earlier, potentially reducing the time and risk involved in the conventional drug-development process.

In their latest announced step, the companies signed a memorandum of understanding to advance clinical validation in Europe and the US through the joint platform. They aim to accelerate international licensing and commercialization of new medicines after trial validation. The companies did not disclose the memorandum’s exact signing date, financial terms, specific drug candidates or a timetable for beginning clinical trials.